Finasteride Cost in Delaware 2026

What Does Finasteride Actually Cost in Delaware?

Generic finasteride at Delaware retail pharmacies averages roughly $12 per month for a 30-tablet supply of 1 mg in 2026. That figure is far below the Merck brand-name Propecia list price of approximately $85 per month, and it sits well under the national average cash price. Prices vary by pharmacy chain, so checking GoodRx or NeedyMeds before filling can shave another $2-$5 off.

The wide price gap between brand and generic reflects standard market dynamics after patent expiration. Finasteride's active patent for androgenetic alopecia (AGA) lapsed years ago, meaning multiple manufacturers now compete on price. The FDA's Orange Book listing for finasteride confirms numerous AB-rated generics that are therapeutically equivalent to Propecia. Because bioequivalence standards require the generic to deliver 80-125% of the reference drug's AUC within 90% confidence intervals, AB-rated substitution is clinically acceptable for most patients [1].

For BPH management, the 5 mg tablet is commonly split or dispensed whole. A 30-count supply of generic finasteride 5 mg at Delaware pharmacies runs approximately $15-$20 per month on cash pay, making it one of the least expensive 5-alpha reductase inhibitor options available [2].

Delaware has 20+ independent and chain pharmacies across New Castle, Kent, and Sussex counties. Costco Pharmacy and Sam's Club Pharmacy (both in Wilmington and Newark) historically post some of the lowest finasteride prices in the state, sometimes as low as $9 per month without any coupon.

How Delaware Medicaid Covers Finasteride

Delaware Medicaid covers finasteride for both AGA and BPH indications, but prior authorization (PA) is required. The PA process asks the prescriber to document clinical indication, confirm the diagnosis code (L64.0 for drug-induced AGA or N40.x for BPH), and attest that the patient meets clinical criteria.

Delaware's Medicaid program is administered through Diamond State Health Plan managed care organizations. Each MCO maintains its own preferred drug list (PDL), and finasteride sits on the PDL as a Tier 1 or Tier 2 drug depending on the MCO. Once PA is approved, member cost-sharing is typically a $1-$3 copay per 30-day fill under standard Delaware Medicaid benefits [3].

The Delaware Division of Medicaid and Medical Assistance (DMMA) publishes PDL updates quarterly. Checking the most current PDL before submitting a PA avoids unnecessary step therapy requirements. If the initial PA is denied, Delaware Medicaid follows federal timelines: standard PA decisions within 14 days, urgent decisions within 72 hours [4].

Dual-eligible patients (Medicare plus Medicaid) should note that Medicare Part D does not cover finasteride for hair loss, as cosmetic indications are excluded under 42 CFR 423.120. Coverage for BPH may differ by Part D plan formulary [5].

Is Compounded Finasteride Legal in Delaware?

Yes. Compounded finasteride is legally dispensed in Delaware by 503A pharmacies operating under a valid patient-specific prescription [6]. Delaware's Board of Pharmacy licenses compounding pharmacies under Title 24, Chapter 25 of the Delaware Code, and state oversight aligns with federal USP 795/797 standards.

503A pharmacies compound finasteride to order for individual patients, typically as oral capsules or topical solutions. They cannot produce finasteride in large batches for office stock under the 503A model, that requires 503B outsourcing-facility registration, and no Delaware-based 503B facility currently lists finasteride as a bulk compounded product.

Compounded finasteride through a Delaware 503A pharmacy runs approximately $45 per month. That is higher than generic retail ($12/month) but lower than brand Propecia ($85/month). The clinical rationale for choosing compounded over generic is narrow: some patients need custom doses (e.g., 0.5 mg daily for side-effect minimization) or specific excipient-free formulations for allergy reasons [7].

The FDA has not placed finasteride on its Category 1 (essentially a copy) or Category 2 (demonstrably difficult to compound) lists, so 503A compounding remains permissible without federal restriction as of January 2025 [6].

Can You Get Finasteride via Telehealth in Delaware?

Telehealth prescribing of finasteride is fully permitted in Delaware. The Delaware Medical Practice Act and the Delaware Telemedicine Act (16 Del. C. Ch. 95) allow licensed physicians and advanced practice providers to establish a patient-provider relationship remotely, conduct a synchronous or asynchronous evaluation, and issue a finasteride prescription without an in-person visit.

A provider still must meet standard prescribing criteria: confirm the diagnosis (AGA or BPH), review contraindications (pregnancy exposure risk, PSA baseline for BPH), and document the clinical encounter. The American Urological Association guideline on BPH recommends obtaining a baseline PSA before starting finasteride 5 mg in men over 50, a step telehealth providers can coordinate through local lab orders [8].

For AGA, Kaufman et al. demonstrated in a key 2-year randomized trial (N=1,553 men, ages 18-41) that finasteride 1 mg daily increased hair count by a mean of 107 hairs per 1-inch target area versus a loss of 50 hairs in the placebo group (P<0.001) [9]. That level of efficacy data supports remote prescribing because the diagnosis is largely clinical and photographic. Several telehealth platforms operating in Delaware (Keeps, Hims, Roman, HealthRX) offer monthly subscriptions that bundle the prescription, follow-up messaging, and pharmacy coordination.

Delaware telehealth providers must hold a Delaware license or qualify under reciprocity. The Delaware Division of Professional Regulation maintains licensee search tools patients can use to verify their telehealth provider's credentials before sharing health information.

Which Insurance Plans Cover Finasteride in Delaware?

Coverage for finasteride varies sharply by indication and plan type. For BPH, most commercial plans in Delaware, including Highmark Blue Cross Blue Shield of Delaware, Aetna, and UnitedHealthcare, list generic finasteride 5 mg on Tier 1 or Tier 2 of their formularies, typically with a $5-$20 copay per 30-day supply [10].

For AGA (hair loss), coverage is inconsistent. Many commercial plans exclude AGA treatment as cosmetic under the same exclusion logic as Medicare. Patients should request a formal formulary exception if their dermatologist or prescriber documents medical necessity beyond cosmesis, for example, documented psychosocial impairment scored on the Dermatology Life Quality Index (DLQI), where scores above 10 indicate a very large effect on quality of life [11].

ACA marketplace plans sold through Delaware's exchange (Get Covered Delaware) are required to cover prescription drugs on their formularies, but formulary inclusion for finasteride AGA is plan-specific. Comparing Summary of Benefits and Coverage (SBC) documents for each plan reveals whether finasteride appears under the applicable drug tier.

Employer self-funded plans (ERISA plans) are exempt from Delaware state insurance mandates, so coverage terms depend entirely on the plan document. HR benefits administrators can confirm finasteride's tier and any step-therapy requirements before the patient fills.

What Is the Cheapest Way to Get Finasteride in Delaware?

Generic finasteride at a high-volume discount pharmacy is the lowest-cost option at roughly $12 per month. Layering a GoodRx or RxSaver coupon on top of that cash price at Walmart, Costco, or Rite Aid can bring the cost to $8-$10 per month in some Delaware ZIP codes.

The ranked cost options from lowest to highest in Delaware in 2026:

1. Generic finasteride + GoodRx coupon at Costco/Walmart: ~$8-$10/month
2. Generic finasteride cash price at chain pharmacy: ~$12/month
3. Insurance copay (Tier 1 BPH indication): ~$5-$20/month (net cost varies)
4. Telehealth subscription bundle (includes Rx + consult): ~$20-$35/month
5. 503A compounded finasteride: ~$45/month
6. Brand-name Propecia without coupon: ~$85/month

Merck offers a savings card for Propecia through its patient assistance portal, which can reduce out-of-pocket cost for eligible commercially insured patients. The card does not apply to government-funded programs (Medicaid, Medicare, CHIP) [12].

NeedyMeds.org lists manufacturer patient assistance programs (PAPs) for brand finasteride. Patients with household income at or below 200-400% of the federal poverty level may qualify for free or near-free medication through these programs [13].

The HealthRX Delaware Cost Tier Framework above reflects aggregated 2026 pharmacy pricing data and is intended as a decision-support guide. Actual pricing should be confirmed at point of sale or through your insurance member portal.

How Finasteride Works: Clinical Background

Finasteride is a selective inhibitor of Type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). DHT is the androgen primarily responsible for follicular miniaturization in genetically susceptible individuals and for prostatic stromal growth in BPH [9].

At 1 mg daily for AGA, finasteride suppresses scalp DHT by approximately 64% and serum DHT by approximately 68% within 42 days of treatment initiation [9]. At 5 mg daily for BPH, serum DHT suppression reaches approximately 70%, with measurable prostate volume reduction of 20-30% at 6-12 months [14].

The FDA-approved prescribing information for finasteride 1 mg states that treatment for at least 3 months is needed before benefit is assessed, with maximum benefit typically seen at 12-24 months [1]. Stopping finasteride reverses DHT suppression within 14 days and leads to loss of treatment-gained hair within 9-12 months in most patients [9].

Sexual side effects (decreased libido, erectile dysfunction, ejaculatory dysfunction) occur in approximately 3.8% of patients on finasteride 1 mg versus 2.1% placebo in the original Phase III trials [9]. Post-finasteride syndrome remains a subject of ongoing study; the FDA's 2012 label update added a warning about persistent sexual dysfunction after discontinuation [1].

Finasteride 5 mg (Proscar) is also used off-label in combination with the alpha-blocker doxazosin; the MTOPS trial (N=3,047) showed combination therapy reduced the risk of BPH clinical progression by 67% versus placebo, compared to 34% for doxazosin alone and 30% for finasteride alone [15].

Delaware-Specific Pharmacy Access

Delaware is a small state with relatively high pharmacy density. New Castle County (Wilmington, Newark, Dover corridor) has the widest selection of retail chains. Sussex County patients (Rehoboth Beach, Seaford, Georgetown) have access through regional independents and mail-order pharmacy options.

Mail-order pharmacy through a Delaware-licensed mail-order facility, including CVS Caremark, Express Scripts, and OptumRx, is legal and common. A 90-day supply via mail order typically costs 2x the 30-day copay, effectively delivering a free 30-day supply each quarter under most commercial plans. For cash-pay patients, a 90-day generic finasteride supply via Costco mail order runs approximately $22-$26, reducing the monthly equivalent to $7-$9 [10].

Delaware Board of Pharmacy regulations require that any out-of-state mail-order pharmacy dispensing to Delaware residents be licensed in its home state and registered with Delaware as a non-resident pharmacy. Patients should verify registration at Delaware's non-resident pharmacy lookup before using an online pharmacy to avoid filling from unlicensed sources.

Monitoring and Follow-Up Requirements

Starting finasteride is not a one-time transaction. Ongoing prescribing in Delaware, whether through a brick-and-mortar dermatologist, urologist, or telehealth provider, requires periodic clinical reassessment.

For BPH patients, the AUA BPH guideline recommends monitoring International Prostate Symptom Score (IPSS) at 3-6 months, then annually. PSA monitoring is essential: finasteride 5 mg lowers PSA by approximately 50% after 6 months, so clinicians should double any PSA value to estimate the true unmasked PSA level when screening for prostate cancer [14]. Failure to account for this effect may delay prostate cancer detection.

For AGA patients, photographic documentation at baseline and 6-12 months helps quantify response. The International Society of Hair Restoration Surgery (ISHRS) recommends standardized photography under consistent lighting conditions as the minimum monitoring standard [16].

Lab monitoring (CBC, LFTs) is not routinely required for finasteride at standard doses, but providers prescribing for BPH in patients over 60 often obtain a baseline PSA and renal function panel given the overlap between BPH symptoms and other urologic pathology [8].

Patients in Delaware with questions about their monitoring schedule can contact the Delaware Division of Public Health for referrals to urologists and dermatologists accepting new patients, including those covered by Delaware Medicaid.